The global antibody drug conjugate market is estimated to grow from USD 7.72 billion in the current year to USD 23.3 billion by 2035, at a CAGR of 9.63% during the forecast period, till 2035.

How is antibody-drug conjugate (ADC) development impacting oncology? Key Takeaways Recent innovations across the multiple ADC components are critical to improving the therapeutic window as we advance ...

A novel conjugate of adalimumab and a proprietary glucocorticoid receptor modulator for patients with PMR led to longer time to flare and fewer flares and reduced the glucocorticoid dose needed.

K-679 is an Antibody Drug-loaded Unimicelle Conjugate (ADUC), a novel type of ADC using Kowa's proprietary micelle technology, currently at non-clinical stage. The conjugate combines an anti-EGFR ...

Antibody Drug Conjugate Market Key Insights The report delves into the current state of the antibody drug conjugate market and identifies potential growth opportunities within the industry.

The drug combines a lab-engineered antibody that recognizes HER3, which is a protein commonly found on the surface of cancer cells, with a powerful cancer-killing agent.

GSK’227 is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm ...

The development of antibody-drug conjugates for the treatment of resistant recurrent cancers has become a hot spot, and promising results have been observed.

Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...

Antibody-drug conjugate found effective against brain metastases in patients with HER2-positive breast cancer Date: September 13, 2024 Source: Dana-Farber Cancer Institute Summary: A drug that ...

Merck's (NYSE: MRK) experimental antibody drug conjugate zilovertamab vedotin, in combination with standard of care, demonstrated encouraging antitumor activity in the phase 2 portion of a study ...